Drug Trial Radar · NCT05740215
Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
158
Planned (sponsor's estimate)
Start
May 23, 2022
Primary completion
May 22, 2024
Study completion May 22, 2024
Sponsor
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Feb 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, phase Ib/II study on the efficacy and safety of F520 combined with lenvatinib in the treatment of patients with advanced solid tumors. About 138\~158 patients with advanced solid tumors plan to be enrolled in about 30 study sites of the study. Part I: Phase Ib study evaluating the safety and tolerability of F520 combined with lenvatinib in patients with advanced solid tumors. Part II: Phase II study of F520 combined with lenvatinib in endometrial cancer and cervical cancer.
Conditions
- Solid Tumors
Interventions
F520Drug
F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
LenvatinibDrug
Lenvatinib capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serious adverse eventsTime frame: 21 days after first dose
- Adverse eventsTime frame: 21 days after first dose
- Dose-limiting toxicity (DLT)Time frame: 21 days after first dose
- Maximum tolerated dose (MTD)Time frame: 21 days after first dose
- Phase II recommended dose (RP2D).Time frame: 21 days after first dose
- Objective Response Rate (ORR)Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.